FDA Vertex Pharmaceuticals

Vertex Pharmaceuticals Shares Gain

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

CNBC on MSN · 11h

FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

The Wall Street Journal on MSN · 10h

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

FDA Approves Vertex Pharma's JOURNAVX As The First Drug In A New Class Of Non-Opioid Pain Medicines

Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...

58m

FDA green lights new painkiller

The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...

News Highlights: Top Company News of the Day - Friday at 1 AM ET

The company has heavily advertised AI features since the latest iPhones were released in September. Revenue rose 10% from a year ago to $9.5 billion. The shift occurs after many brands cut their ...

precisionmedicineonline3h

NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results